Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
All entries in pancreatic cancer
- Trial result
Pancreatic cancer
Oral Salmonella-IL2 bacteria + systemic FOLFIRINOX triples median PFS to 15 mo in stage IV pancreatic cancer
Salmonella-IL2, an attenuated *S. Typhimurium* engineered to secrete human IL-2 and colonize tumors, was administered orally alongside bi-weekly FOLFIRINOX in a non-randomized Phase II study (NCT04589234). 20…
NCT04589234 - Trial result
Pancreatic cancer
Motixafortide (CXCR4i) + cemiplimab/PD-1 with gem/nab-paclitaxel logs 63% PR and 9.6-mo PFS in 1L metastatic PDAC
In the Phase 1 “signal-seeking” CheMo4METPANC study (NCT04543071), eleven treatment-naïve patients with metastatic pancreatic cancer received motixafortide (CXCR4i), cemiplimab, gemcitabine (1000 mg/m²) +…
NCT04543071 - Trial result
Pancreatic cancer
Surufatinib (VEGFR/FGFR/CSF-1R TKI) + KN046 (PD-L1/CTLA-4 bispecific) with gem/nab-paclitaxel delivers 69% ORR in first-line advanced pancreatic cancer
Surufatinib, an oral multi-kinase inhibitor of VEGFR1-3, FGFR1 and CSF-1R, was combined with KN046, a dual PD-L1/CTLA-4 antibody, and the chemotherapy backbone gemcitabine 1000 mg/m² + nab-paclitaxel 125 mg/m² (q3w)…
NCT05832892 - Trial result
Pancreatic cancer
Avutometinib (RAF/MEK clamp) + defactinib (FAK i) with gem/nab-paclitaxel pushes ORR to 83% in first-line metastatic PDAC
Avutometinib and defactinib were combined with standard gemcitabine (800–1000 mg/m)² + nab-paclitaxel (100–125 mg/m²) in the Phase Ib/II RAMP-205 trial (NCT05669482). Among 54 newly diagnosed metastatic PDAC patients…
NCT05669482 - Trial result
Pancreatic cancer
Adaptive FOLFIRINOX→gem/nab-paclitaxel (plus losartan) drives 88–100% R0 resections in localized pancreatic cancer
The NeoOPTIMIZE study evaluated a “fail-fast” neoadjuvant strategy: 43 resectable/borderline/locally advanced PDAC patients began with four cycles of FOLFIRINOX + daily losartan (angiotensin II receptor blocker…
- New trial
Pancreatic cancer
Phase I Trial of Adaptive Radiation Therapy for Pancreatic Cancer with CT Marker Guidance
Fox Chase Cancer Center is assessing the safety and efficacy of Adaptive Radiation Therapy in patients with locally advanced, unresectable pancreatic cancer. The study uses CT-based planning with 1–3 markers placed…
NCT06984562 - New trial
Pancreatic cancer
Phase 1 Trial of Cosibelimab and Balixafortide Targeting PD-L1 and CXCR4 in Metastatic PDAC
An open-label phase 1 study at Cedars-Sinai is evaluating the safety and tolerability of cosibelimab—a PD-L1 directed monoclonal antibody—and balixafortide, a CXCR4 inhibitor, in metastatic pancreatic ductal…
NCT06981806 - New trial
Pancreatic cancer
Pilot Study of Tamoxifen (Estrogen Receptor Inhibitor) in Pre-Invasive Pancreas MCN
The University of Nebraska is conducting an open‐label pilot study enrolling up to 15 participants with pancreatic MCN who won't undergo immediate resection, to assess the feasibility of 20mg daily tamoxifen over 6…
NCT06320990 - New trial
Pancreatic cancer
A Pilot Study Comparing Neoadjuvant and Adjuvant GVAX vs a Mutated KRAS Peptide Vaccine Given With Anti-PD-1 and Anti-CD137 for the Treatment of Surgically Resectable Pancreatic Adenocarcinoma
Johns Hopkins is investigating the optimal dosing and safety of AGEN2373 combined with balstilimab alongside either GVAX or a mutated KRAS peptide vaccine, aimed at enhancing neoadjuvant and adjuvant treatment…
NCT06782932 - New trial
Pancreatic cancer
A Window of Opportunity Strategy for Targeted Pathway Inhibition in Patients With Pancreatic Ductal Adenocarcinoma
This early phase I trial from OHSU is investigating multiple targeted agents (cobimetinib, olaparib, onvansertib, azenosertib, AZD5305, and tremelimumab) in advanced pancreatic cancer through pre- and post-treatment…
NCT04005690 - New trial
Pancreatic cancer
Phase I/II Clinical Trial of Ontegimod and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma: Reprogramming Tumor-associated Myeloid Cells
Investigators at WashU are testing whether CD11b agonism can reprogram the tumor microenvironment to overcome resistance to checkpoint immunotherapy in advanced, unresectable pancreatic adenocarcinoma. The open-label…
NCT06904378 - New trial
Pancreatic cancer
Phase Ib Study: PTM-101 as an Adjunct to Neoadjuvant Therapy in Advanced PDAC
PanTher Therapeutics is evaluating PTM-101—a PLZ4-coated paclitaxel-loaded micelle nanoparticle—in combination with standard neoadjuvant chemotherapy in treatment-naïve patients with borderline resectable or locally…
NCT06673017 - Trial result
Pancreatic cancer
CM24 Combo Yields Survival Benefit in Pancreatic Cancer Patients with Specific Serum Biomarker Profiles
In this Phase 2 study, the addition of CM24 and nivolumab to chemotherapy in advanced PDAC showed modest overall improvements in survival and response rates, but subgroup analyses reveal that patients with…
- New trial
Pancreatic cancer
Phase II Study Combines NC410, FOLFIRINOX, and Immune Modulators in Metastatic PDAC
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins is investigating the safety profile and potential novel toxicities of NC410 combined with FOLFIRINOX and checkpoint inhibitors (nivolumab with or without…
NCT06941857 - New trial
Pancreatic cancer
Phase I Study Evaluates Bosentan with Gemcitabine and Nab-Paclitaxel in Unresectable Pancreatic Cancer
City of Hope Medical Center is testing the optimal dose and safety of bosentan—an endothelin receptor inhibitor—when combined with standard chemotherapy (gemcitabine and nab-paclitaxel) in patients with unresectable…
NCT04158635
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.